Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Status Enrolling by invitation

Clinical Trial Summary

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398 001) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Achondroplasia

Clinical Trial Details

NCT number	NCT05145010
Study type	Interventional
Source	QED Therapeutics, Inc.
Contact
Status	Enrolling by invitation
Phase	Phase 2
Start date	December 6, 2021
Completion date	February 1, 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05353192` - A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia	Phase 4
Recruiting	`NCT05328050` - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Completed	`NCT05659719` - A Study to Learn About Recifercept in Patients With Achondroplasia
Active, not recruiting	`NCT04554940` - A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia	Phase 2
Completed	`NCT01435629` - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin	N/A
Enrolling by invitation	`NCT06164951` - A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia	Phase 3
Completed	`NCT01516229` - Special Survey for Long Term Application	N/A
Completed	`NCT03872531` - Lifetime Impact Study for Achondroplasia
Active, not recruiting	`NCT05598320` - A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia	Phase 2/Phase 3
Terminated	`NCT05813314` - Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants	Phase 1
Recruiting	`NCT04265651` - Study of Infigratinib in Children With Achondroplasia	Phase 2
Recruiting	`NCT05603936` - Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
Completed	`NCT03780153` - The Norwegian Adult Achondroplasia Study
Active, not recruiting	`NCT04085523` - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia	Phase 2
Enrolling by invitation	`NCT05929807` - A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia	Phase 2/Phase 3
Not yet recruiting	`NCT06433557` - A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia	Phase 2
Completed	`NCT03875534` - A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
Terminated	`NCT03794609` - Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
Completed	`NCT03583697` - A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia	Phase 2
Active, not recruiting	`NCT03989947` - An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia	Phase 2